The patient was diagnosed with bronchogenic adenocarcinoma and received carboplatin, pemetrexed, and pembrolizumab, which alleviated the esophageal stricture and cancerous lymphangiopathy. However, the adenocarcinoma progressed, and she subsequently received several rounds of chemotherapy. One year after ...
Carboplatin/pembrolizumab/pemetrexed. Reactions Weekly 1779, 59 (2019). https://doi.org/10.1007/s40278-019-71323-1 Download citation Published16 November 2019 Issue DateNovember 2019 DOIhttps://doi.org/10.1007/s40278-019-71323-1 Access this article Log in via an institution Subscribe and save...
The requested medication will be used as single agent or in combination with pemetrexed for maintenance therapy;or The requested medication will be used in combination with pemetrexed and either carboplatin or cisplatin for nonsquamous cell histology;or The requested medication will be used in combinati...
1文献来源Langer CJ,Gadgeel SM,Borghaei H,et al.Carboplatin and Pemetrexed with or without Pembrolizumab for advanced,non-squamous non-small-cell lung cance... 范云,张嘉涛 - 《循证医学》 被引量: 1发表: 2017年 Comparative efficacy and safety of second-line treatments for advanced non-small...
The patients will be randomized 1:1 to pembrolizumab (200 mg) or pembrolizumab (200 mg) plus carboplatin (area under the curve 5) plus pemetrexed (500 mg/m2) on day 1 of each 21-day treatment cycle. The primary endpoint is progression-free survival. The recruitment phase began in August...
Thirty patients received pembrolizumab as monotherapy, 1 patient received combination therapy of pembroli‑ zumab with carboplatin and pemetrexed, and 2 patients received pembrolizumab combined with radiation therapy. Time to onset of CIP in the 33 patients was 1 day at the shortest and 2 years ...
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomi...
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic t...
(27.8) Ad, adenocarcinoma; PD-L1, programmed cell death-ligand 1; PEM, pemetrexed; Pembro, pembroli- zumab, PSM, propensity score matching; PTX, paclitaxel; nab-PTX, nanoparticle albumin-bound pacli- taxel; Sq, squamous cell carcinoma; TPS, tumor proportion score group (11.3 months vs...
Carboplatin/pemetrexedd,e 54 (37.5) 27 (37.0) 27 (38.0) 0.18i Cisplatin/pemetrexedd,e 46 (31.9) 24 (32.9) 22 (31.0) Platinum ±pemetrexed ±otherd 30 (20.8) 13 (17.8) 17 (23.9) Cisplatin/pemetrexed and carboplatin/pemetrexedd 8 (5.5) 7 (9.6) 1 (1.4) Missinge 6 (4.2) 2 ...